Genomic investigations of acute myeloid leukemia (AML) have demonstrated that several
genes are recurrently mutated, leading to new genomic classifications, predictive biomarkers, …

FMS-like tyrosine kinase-3 (FLT3), a receptor tyrosine kinase, is important for the
development of the hematopoietic and immune systems. Activating mutations of FLT3 are now …

Cornelia de Lange syndrome (CdLS) is an archetypical genetic syndrome that is characterized
by intellectual disability, well-defined facial features, upper limb anomalies and atypical …

Background Patients with relapsed or refractory acute myeloid leukemia (AML) with mutations
in the FMS-like tyrosine kinase 3 gene (FLT3) infrequently have a response to salvage …

Activating mutations of FMS-like tyrosine kinase 3 (FLT3) are present in approximately 30%
of patients with de novo acute myeloid leukemia (AML) and are associated with lower cure …

Activating mutations in the receptor tyrosine kinase FLT3 are present in up to approximately
30% of acute myeloid leukemia (AML) patients, implicating FLT3 as a driver of the disease …

SDF-1α/CXCR4 signaling plays a key role in leukemia/bone marrow microenvironment
interactions. We previously reported that bone marrow–derived stromal cells inhibit …

Effective targeted cancer therapeutic development depends upon distinguishing disease-associated
‘driver’ mutations, which have causative roles in malignancy pathogenesis, from ‘…

… Like the FTA, this is als weighted index; it comprises the lowest ten per capitalization of the
Main and USM equity m about 1,600 firms - and is rebalanced annually. A the HGSC Index is …

… mitoxantrone 8 mg/m 2 per day, etoposide 100 mg/m 2 , and cytarabine 1000 mg/m 2 per day
… 24 months received HiDAC, consisting of cytarabine 1500 mg/m 2 daily on days 1 to 5. For …